Study of Depression-Ketamine-Brain Function

Phase 2

Terminated

• Conditions: Major Depression
• Interventions: Drug: Ketamine

• Registration Number: NCT01135758
• Lead Sponsor: Markus KOSEL

Brief Summary

Targeting the glutamatergic system to treat depression is a new and promising strategy based on studies at the molecular, synaptic, and neuronal level but also on results of studies conducted in animal models and first clinical studies involving depressed patients.Ketamine has been proposed as a novel approach to induce rapid antidepressant response. In this pilot project the investigators aim to introduce this novel and promising approach into clinical practice. Besides the assessment of clinical efficacy, the investigators will put a special emphasis on the assessment of ketamine-associated effects on brain function using fMRI and cognitive testing.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06
• Study First Submitted: 2010-06-02
• Study First Submitted QC: 2010-06-02
• Study First Posted: 2010-06-03
• Primary Completion: 2015-06
• Study Completion: 2015-09
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-04
• Last Update Posted: 2015-12-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Men and women aged 18 to 65 years with a diagnosis of major depressive disorder without psychotic features.
• Drug-resistant depressed patients (defined as non-response to two sufficiently long (at least 6 weeks) drug trials at the maximal authorized or tolerated dose)
• Score 25 or higher on the Montgomery-Asberg Depression Rating Scale
• Stable psychotropic medication (antidepressants, antipsychotics, mood stabilizers) during the last 6 weeks prior to inclusion.
• Legally competent subjects agreeing to comply with the requirements of the study and authorizing the transmission of relevant information to competent physicians in the case of a clinically relevant previously unknown finding during an MRI examination.

Exclusion Criteria

• Subjects with co-morbid substance abuse or dependence during the 3 months prior to inclusion, except nicotine consumption.
• Patients judged to be at serious suicide risk (score ≥ 4 at item 10 of the MADRS).
• Patients with any other DSM-IV axis one diagnosis including bipolar disorder except for anxiety disorder which are not dominating the clinical presentation.
• History of antidepressant or substance-induced hypomania or mania.
• History of psychotic symptoms.
• Patients with any contra-indication to the administration of ketamine, especially present diagnosis or antecedents of clinically relevant cardiovascular disorders (clinically significant or not adequately treated hypertension, present or previous diagnosis of cardiovascular disorder such as stroke or heart attack etc).
• Any MRI contraindication, especially metallic implants, pacemaker, etc.
• Pregnant women, breast-feeding women, women of childbearing age without effective means of contraception.
• Treatment during the last 2 weeks with thyroid hormones and sympathicomimetic drug.
• Present or past diagnosis of eclampsia or preeclampsia.
• Untreated or insufficiently treated hyperthyroidism.
• Known hypersensitivity to ketamine or to the excipient (benzethonium chloride).
• Present or past diagnosis of glaucoma, intracranial hypertension.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ketamine 0.5 mg/kg i.v.	Ketamine	Single administration of ketamine 0.5 mg/kg i.v.

Primary Outcome Measures

Name	Time	Method
Difference of the MADRS score at baseline and after ketamine injection	40, 80, 110, 230 min, 1, 2, 3, 6, 7, 10 d after ketamine administration

Trial Locations

Locations (1)

Service de Psychiatrie Adulte, Programme dépression; 🇨🇭 Geneva, Switzerland